3-叔丁基-4-羟基苯甲腈 | 4910-04-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-叔丁基-4-羟基苯甲腈
• 英文名称: 3-(1,1-dimethylethyl)-4-hydroxybenzonitrile
• 英文别名: 3-(tert-butyl)-4-hydroxybenzonitrile；3-tert-butyl-4-hydroxybenzonitrile
• CAS: 4910-04-7
• 化学式: C₁₁H₁₃NO
• 分子量: 175.23
• InChiKey: WOQNZPYFQSOAJS-UHFFFAOYSA-N

物化性质

• 沸点：
  293.5±28.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  44
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2926909090
• 危险性防范说明：
  P261,P273,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335,H412

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(tert-Butyl)-4-hydroxybenzonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(tert-Butyl)-4-hydroxybenzonitrile
CAS number: 4910-04-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H13NO
Molecular weight: 175.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-叔丁基-4-羟基苯甲腈 在 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 以9.7 g的产率得到3-叔丁基-4-羟基苯甲酸
  参考文献：
  名称：

  用于不对称烯烃环氧化的等网状手性金属-有机骨架：通过控制骨架链和改变开放通道尺寸来调节催化活性

  摘要：

  由 [Zn(4)(μ(4)-O)(O(2)CR)(6)] 二级构建单元和系统地构建原始立方网络拓扑的一系列等网状手性金属有机框架 (CMOF)衍生自手性 Mn-Salen 催化亚基的延长的二羧酸盐支柱。CMOFs 1-5 是通过在溶剂热条件下将三种不同的手性 Mn-Salen 支柱直接掺入骨架中而合成的，并通过多种方法对其进行表征，包括单晶 X 射线衍射、PXRD、TGA 和 (1)核磁共振。尽管 CMOFs 1 vs 2 和 CMOFs 3 vs 4 对是由相同的构建块构建的，但它们分别表现出双重互穿或非互穿结构，具体取决于用于生长 MOF 晶体的溶剂的空间尺寸. 对于 CMOF-5，由于 Mn-Salen 衍生的二羧酸盐支柱的极端长度，仅获得了三重互穿结构。由于可调节的二羧酸支柱和可控的互穿模式，CMOF 系列的开放通道和孔径大小有系统地变化。CMOF 1-5 被证明是一种高效的催化剂

  DOI：

  10.1021/ja1069773
• 作为产物：
  描述：

  2-叔丁基苯酚 在 1,4-dioxane dibromide 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.53h， 生成 3-叔丁基-4-羟基苯甲腈
  参考文献：
  名称：

  不同取代的 tacn 基配体的合成：控制铀配位配合物的溶解度和电子和空间特性

  摘要：

  从酚类 R1,R2ArOH (5) 和苯甲醚衍生物 3,5-di-tert-butyl-2-methoxybenzyl bromide (13) 开始，一系列新的基于 tacn 的配体 (R1,R2ArOR3)3tacn (2) 已经被在相对于氧配位点的邻位和对位上合成了具有不同体积和电子性质的取代基。据观察，这些基团不仅决定了 2 的空间屏蔽和溶解度特性，而且当在 5 中的对位引入吸电子基团时，还使酚类在改性曼尼希反应中的反应性失活。 thf 中的 UCl4 导致了四种铀 (IV) 氯络合物 [{(R1,R2ArO)3tacn}UIVCl] (14) 的分离，它们通过不同的光谱和物理方法（例如 1H NMR、UV/Vis、SQUID ), 证实了 14 中的 +4 氧化态。单晶 X 射线结构分析显示 14a·CH2Cl2·CH3CN 和 14b·1.25CH2Cl2 在手性正交空间群 P212121

  DOI：

  10.1002/ejic.201201549

文献信息

• HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS
  申请人：Alvaro Giuseppe

  公开号：US20130267510A1

  公开（公告）日：2013-10-10

  The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

  该发明提供了化合物的公式(I)：所述化合物是Kv3通道的抑制剂，可用于预防或治疗相关疾病。
• [EN] PYRROLIDINE-2-CARBONITRILE DERIVATIVES AND THEIR USE AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV)<br/>[FR] DERIVES DE PYRROLIDINE-2-CARBONITRILE ET LEUR UTILISATION COMME INHIBITEURS DE LA DIPEPTIDYLE PEPTIDASE-IV (DPP-IV)
  申请人：ABBOTT LAB

  公开号：WO2005023762A1

  公开（公告）日：2005-03-17

  The present invention relates to compounds of formula (I), (I), which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, b-cell failure, obesity, satiety disorders, atherosclerosis, and various immunomodulatory diseases.

  本发明涉及式(I)、(I)的化合物，其抑制二肽基肽酶IV（DPP-IV），并且对于预防或治疗糖尿病，特别是II型糖尿病，以及高血糖、X综合征、高胰岛素血症、β细胞功能衰竭、肥胖、饱腹障碍、动脉粥样硬化和各种免疫调节性疾病有用。
• [EN] SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS SUBSTITUÉS PAR PYRIDINYLE ET LEURS UTILISATIONS
  申请人：BIONOMICS LTD

  公开号：WO2019222816A1

  公开（公告）日：2019-11-28

  The present application relates generally to compounds useful for the treatment and/or enhancement of cognitive dysfunction and negative symptoms associated with CNS disorders where the circuitry involving fast spiking PV+ interneurons and the production of cortical gamma oscillations is disrupted. The subject disclosure enables the manufacture of medicaments as well as compositions containing same for use in methods of therapy and prophylaxis of cognitive dysfunction and negative symptoms.

  本申请一般涉及用于治疗和/或增强与中枢神经系统疾病相关的认知功能障碍和负性症状的化合物。其中，涉及快速尖峰PV+抑制神经元和皮层γ波振荡产生的电路被破坏。该主题披露使得制造药物以及含有相同化合物的组合物成为可能，用于治疗和预防认知功能障碍和负性症状的方法。
• [EN] IMIDAZOLIDINEDIONE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZOLIDINEDIONE
  申请人：GLAXO GROUP LTD

  公开号：WO2011069951A1

  公开（公告）日：2011-06-16

  The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.

  这项发明提供了化合物(Ia)及其药学上可接受的盐。该发明还提供了将这些化合物或盐用作Kv3.1和/或Kv3.2的调节剂，以及在需要Kv3.1和/或Kv3.2调节剂的疾病或紊乱的治疗中的用途，如抑郁症和情绪障碍、听觉障碍、精神分裂症、物质滥用障碍、睡眠障碍或癫痫病。
• [EN] HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS<br/>[FR] DÉRIVÉS D'HYDANTOÏNE UTILES EN TANT QU'INHIBITEURS DE KV3
  申请人：AUTIFONY THERAPEUTICS LTD

  公开号：WO2012076877A1

  公开（公告）日：2012-06-14

  The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

  该发明提供了化合物的公式(I)：所述化合物是Kv3通道的抑制剂，可用于预防或治疗相关疾病。